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Percutaneous Coronary
Revascularization for
Myocardial Infarction in
Chronic Kidney Disease
Recognizing the Risk While Seizing the Benefits*
Patricia J. M. Best, MD
Rochester, Minnesota
Chronic kidney disease (CKD) with an estimated glomer-
ular filtration rate 60 ml/min is seen in over 30% of
patients undergoing percutaneous coronary intervention
(PCI) (1). The prevalence of CKD continues to rise, in
part because of increasing diabetes and hypertension (2).
In patients undergoing PCI for either stable coronary
artery disease or acute myocardial infarction, CKD is one
of the strongest risk factors for short- and long-term
mortality (1,3).
See page 1002
PCI is an important modality of reperfusion therapy in
ST-segment elevation myocardial infarction. When CKD is
present, regardless of the increased risk of death from
myocardial infarction, PCI is underutilized. Although the
reason is not entirely clear, it likely reflects the comorbidities
of the population (4) as well as the desire to avoid the
consequential and increased risks of PCI complications,
such as bleeding and contrast-induced nephropathy. In the
Global Registry of Acute Coronary Events study, primary
PCI compared with fibrinolysis is associated with a similar
reduction in mortality in patients with normal renal func-
tion and those with moderate CKD (5). Additional ST-
segment elevation myocardial infarction studies in CKD
patients have shown mortality reduction with reperfusion by
fibrinolysis or PCI (6,7).
In non–ST-segment elevation myocardial infarction, the
benefit of revascularization in the CKD patient has not been
established. The study by Hanna et al. (8) in this issue of
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evaluate CKD in non–ST-segment elevation myocardial
infarction patients only. Patients were evaluated from the
National Cardiovascular Data Registry (NCDR)—Acute
Coronary Treatment and Intervention Outcomes Network–
Get With the Guidelines (ACTION-GWTG) registry.
This study excluded patients not undergoing PCI to de-
crease the impact of the sickest patients with CKD not
being treated with PCI. They found that CKD was a strong
predictor of in-hospital mortality, with an odds ratio of 2.0
at Stage 3 CKD compared with those with normal renal
function, and increasing to 2.8 in those with Stage 4 CKD.
Additionally, as has been seen with other studies (6,9),
CKD patients received less standard medical therapy within
the first 24 h, including aspirin, clopidogrel, statin therapy,
and beta-blockers. In this registry, even with the higher use
of bivalirudin in the CKD patients, they still had a 2.8-fold
increased risk of major bleeding in the Stage 4 CKD group
compared with those with normal renal function.
CKD has been well established as a risk for bleeding
complications following PCI and is associated with a graded
risk of bleeding over 4 times higher in those with a
glomerular filtration rate 30 ml/min compared with those
75 ml/min (10). Given the baseline anemia frequently
seen in this population, the ability to tolerate bleeding
events may be compromised. In all patients, regardless of
renal function, bleeding after PCI is associated with in-
creased mortality (11). Bivalirudin reduces bleeding com-
plications associated with PCI, particularly in those with
CKD (12–14). Vascular closure devices or a radial access
approach may further reduce bleeding events.
Another important complication associated with CKD is
contrast-induced nephropathy. This risk is heightened in
patients with an acute myocardial infarction. Contrast-
induced nephropathy is a strong and powerful predictor of
in-hospital and long-term major adverse cardiovascular
events and mortality (15). Although multiple mechanisms
to reduce this risk have been tried, hydration and limiting
the contrast dose are most effective. Still, the risk of
contrast-induced nephropathy may inhibit the appropriate
use of coronary angiography and percutaneous coronary
revascularization in CKD patients likely to benefit.
Restrained use of PCI in the CKD population has also
stemmed from the high restenosis risk seen in the balloon
angioplasty era with renal failure patients. Bare-metal stent-
ing in mild and moderate CKD is not associated with
increased restenosis (16). With drug-eluting stents in those
with nondialysis-dependent CKD, restenosis is not in-
creased compared with those with normal renal function
(17,18). However, hemodialysis remains an important risk
for restenosis, even using drug-eluting stents. Adding to the
complexity in managing the bleeding risk in the CKD
patients is that even after a successful PCI, CKD is
associated with increased stent thrombosis.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 4 , N O . 9 , 2 0 1 1
S E P T E M B E R 2 0 1 1 : 1 0 0 9 – 1 0
Best
Editorial Comment
1010We will continue to frequently see patients with CKD and
an acute myocardial infarction. The paucity of data in this
population is quite concerning, given that special characteristics
exist, such as altered platelet function leading to increased
bleeding and thrombotic risk, and increased inflammation.
The study by Hanna et al. (8) is an important initial step into
the understanding of outcomes in this population. Further
studies will be needed to better define the best adjuvant
therapy with PCI and to look for therapies specific and
targeted to mechanisms of disease progression associated
with CKD.
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